Grindr Launches In-App Access to Sexual Health and Safety Resources in 30 Countries Around the World
11.7.2024 16:00:00 EEST | Business Wire | Press release
Grindr Inc. (NYSE:GRND), the premier LGBTQ+ social connector, today announced it has partnered with several organizations to launch in-app access to sexual health and safety resources for its users in 30 countries around the world. This wide-reaching program is led by Grindr for Equality, the company’s social impact initiative. Grindr users across 30 countries, including Brazil, Kenya, Spain, and Namibia, are now able to access these vital sexual health and safety resources directly through a side drawer on the Grindr app’s home screen, gaining localized and real-time information on the issues that matter to them the most.
Since 2015, Grindr for Equality has worked towards a world where the lives of Grindr users and the global LGBTQ+ community are free, equal, and just, advancing initiatives that impact communities on issues such as safety and sexual health. Lack of access to HIV testing is one of the biggest obstacles in the fight against the global HIV epidemic, posing a particular burden for some Grindr users, such as those living in rural areas or those who are not “out” to their families. Additionally, anti-LGBTQ+ legislation threatens the safety of members of the queer community every day by criminalizing their fundamental identities. With its new partnerships and its ongoing work, Grindr for Equality aims to empower users with real-time access to critical information that helps combat this adversity.
The new safety and sexual health resources available on the Grindr platform are led by Grindr for Equality’s partnership with European Test Finder, a free online tool that helps users find nearby locations for testing and treatment of HIV, Tuberculosis, Hepatitis B and C, and other STIs across the WHO European region. Grindr users across 24 countries supported by European Test Finder, including Austria, Belgium, Cyprus, France, Serbia, Slovakia, and Ukraine, are now able to quickly access vital public health services directly on Grindr. Grindr for Equality is also partnering with Ceska spolecnost aids pomoc, IntraHealth Namibia, IVOR Foundation, and The Love Tank to make additional sexual and mental health resources available to Grindr users in Czechia, Namibia, Bulgaria, and the United Kingdom, respectively.
In Brazil, Grindr for Equality is partnering with Ministério da Saúde, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis to provide in-app access to Onde encontrar a PrEP, a PrEP service locator. Grindr for Equality is also partnering with GALCK+ to provide Grindr users in Kenya with in-app access to Know Your Rights, a safety page designed to empower the Kenyan LGBQ community by informing them of their rights.
“Grindr is proud to partner with groups like CHIP and the EuroTEST Initiative that are hosting the European Test Finder to increase access to essential sexual health and safety resources for users around the world,” said Steph Niaupari of Grindr for Equality. “We’ve seen how in-app resources can help drive meaningful public health outcomes for the LGBTQ+ community, and we look forward to expanding the impact Grindr is able to achieve by providing a wider range of sexual health and safety resources to more of our global users.”
“We are thrilled to partner with Grindr to widen access to crucial testing and treatment for life-altering conditions such as HIV, Tuberculosis, and Hepatitis,” said Cæcilie Bom Kahama, project coordinator for the European Test Finder, at the secretariat of the EuroTEST Initiative, at CHIP in Denmark. “By helping more individuals quickly and easily access these public health services, Grindr is taking concrete steps to promote early diagnosis and care. We are grateful for the company’s leadership on this matter and hope this will encourage more people to test regularly and ultimately help reduce overall transmission.”
Today’s announcement builds on the success of Grindr for Equality’s existing partnerships to distribute free at-home HIV test kits directly to Grindr users across a growing list of countries including Georgia, Ireland, New Zealand, and the United States, as well as the City of London. In partnership with organizations including Building Healthy Online Communities, these programs have distributed more than 440,000 test kits to date. Grindr for Equality plans to launch similar initiatives and bring additional safety, sexual health, and advocacy resources to more Grindr users and members of the LGBTQ+ community around the world.
About Grindr Inc.
With more than 13.7 million monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015 Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711785938/en/
Contacts
Media:
Press@grindr.com
Investors:
IR@grindr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom